Taiho “Primed And Ready To Go” With Colon Cancer Drug Lonsurf

After fast approval of oral chemotherapy combination Lonsurf for late-line colon cancer, U.S. oncology newcomer and Otsuka Holdings subsidiary plans to launch within two weeks at a reasonable price, says CEO Eric Benn.

Taiho Pharmaceutical Co. Ltd.’s US oncology division scored its first FDA approval Sept. 22 with early clearance of the oral fixed chemotherapy combination Lonsurf (trifluridine/tipiracil) in a very narrow indication for late-line treatment of metastatic colon cancer.

Taiho Oncology’s candidate (TAS-102) was approved for metastatic colorectal cancer (mCRC) in patients who already had fluoropyrimidine-, oxaliplatin- and irinotecan-...

More from Clinical Trials

More from R&D